JETEMA, Co., Ltd.

KOSDAQ 216080.KQ

JETEMA, Co., Ltd. Capital Expenditure for the year ending December 31, 2023: USD -5.54 M

JETEMA, Co., Ltd. Capital Expenditure is USD -5.54 M for the year ending December 31, 2023, a 89.05% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • JETEMA, Co., Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -50.55 M, a -271.22% change year over year.
  • JETEMA, Co., Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -13.62 M, a -361.10% change year over year.
  • JETEMA, Co., Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -2.95 M, a 73.72% change year over year.
  • JETEMA, Co., Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -11.24 M, a 0.87% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
SV Wall Street
KOSDAQ: 216080.KQ

JETEMA, Co., Ltd.

CEO Jeong Sun Nam
IPO Date Nov. 14, 2019
Location South Korea
Headquarters 1283-4, Gagok-ri
Employees 227
Sector Healthcare
Industries
Biotechnology 3D Printing Cosmetics Dental Care Eyewear Personal Care Pharmaceuticals Plastics
Description

JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers botulinum toxins, fillers, anti-aging solutions, lifting threads for medical treatment, laser surgical instruments, and skin care hyaluronic acid masks. The company is headquartered in Wonju, South Korea.

StockViz Staff

February 5, 2025

Any question? Send us an email